Testing Antifungal Vaccines in an Animal Model of Invasive Candidiasis and in Human Mucosal Candidiasis

Segal, Esther

doi:10.1007/978-1-4939-7104-6_23

Cited by 7 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The immunization step is then followed by a challenge of the immunized animals with live microorganisms, and the degree of protection to withstand the challenge is assessed in comparison to non-vaccinated control animals [ 20 ]. Such experiments were extensively reported in the literature with various Candida immunogens, such as killed Candida , attenuated live organisms, or various subcellular Candida fractions [ 24 , 25 , 26 , 27 ], including studies by the author’s group using Candida ribosomes as an immunogen [ 20 ].…”

Section: The Mouse Modelmentioning

confidence: 99%

Experimental In Vivo Models of Candidiasis

Segal

Frenkel

2018

JoF

Self Cite

View full text Add to dashboard Cite

Candidiasis is a multifaceted fungal disease including mucosal-cutaneous, visceral, and disseminated infections caused by yeast species of the genus Candida. Candida infections are among the most common human mycoses. Candida species are the third to fourth most common isolates from bloodstream infections in neutropenic or immunocompromised hospitalized patients. The mucosal-cutaneous forms-particularly vaginal infections-have a high prevalence. Vaginitis caused by Candida species is the second most common vaginal infection. Hence, candidiasis is a major subject for research, including experimental in vivo models to study pathogenesis, prevention, or therapy of the disease. The following review article will focus on various experimental in vivo models in different laboratory animals, such as mammals (mice, rats, rabbits), the fruit fly-Drosophila melanogaster, the larvae of the moth Galleria mellonella, or the free-living nematode Caenorhabditis elegans. The review will describe the induction of the different clinical forms of candidiasis in the various models and the validity of such models in mimicking the human clinical situations. The use of such models for the assessment of antifungal drugs, evaluation of potential vaccines to protect before candidiasis, exploration of Candida virulence factors, and comparison of pathogenicity of different Candida species will be included in the review. All of the above will be reported as based on published studies of numerous investigators as well as on the research of the author and his group.

show abstract

Section: The Mouse Modelmentioning

confidence: 99%

Experimental In Vivo Models of Candidiasis

Segal

Frenkel

2018

JoF

Self Cite

View full text Add to dashboard Cite

show abstract

“…Protein that belonging to Sap (Sap 2) family [20,21] and b. Als (Als 9) proteins have been completed phase I trials and approved for RVVC treatment.…”

Section: Development Of New Strategies For Candida Vaccinationmentioning

confidence: 99%

“…Recently, the data demonstrated the importance of Sap 2 against mucosal infections of C. albicans with some formulation by virosomes in order to develop better vaccine for candidiasis [21].…”

Section: Development Of New Strategies For Candida Vaccinationmentioning

confidence: 99%

Old Wine in a New Bottle-Focus on Candidial Vaccine

saran

2018

IGRWH

View full text Add to dashboard Cite

Vaginal Candidacies or vaginal candidial infection is one of the most common infections in reproductive age and older age woman. It is usually managed by first line treatment of azoles and other antifungal antibiotics through oral, tropical and intra-vaginal preparations. Followed by if recurrence observed, intravenous preparation also administrated. During the past decades, the incidence of vaginal candidiasis and recurrent vaginal Candidiasis was frequently occurred due to poor/ mis-diagnosis, development of drug resistance, infection by non albicans species, phenotypic and genetic adaptation towards the drug Candidate. Even though, there are enormous new antifungal antibiotics was introduced but the incidence of drug resistance was more concern. So in order to overcome this circumstance the researchers are tend to make a new Candida to prevent the Candida infection. In this review we are trying to achieve the importance Candida vaccine thus should provide a better option for candidiasis.

show abstract

Nanotools for Sepsis Diagnosis and Treatment

Papafilippou

Claxton

Dark

et al. 2020

Adv Healthcare Materials

View full text Add to dashboard Cite

Sepsis is one of the leading causes of death worldwide with high mortality rates and a pathological complexity hindering early and accurate diagnosis. Today, laboratory culture tests are the epitome of pathogen recognition in sepsis. However, their consistency remains an issue of controversy with false negative results often observed. Clinically used blood markers, C reactive protein (CRP) and procalcitonin (PCT) are indicators of an acute‐phase response and thus lack specificity, offering limited diagnostic efficacy. In addition to poor diagnosis, inefficient drug delivery and the increasing prevalence of antibiotic‐resistant microorganisms constitute significant barriers in antibiotic stewardship and impede effective therapy. These challenges have prompted the exploration for alternative strategies that pursue accurate diagnosis and effective treatment. Nanomaterials are examined for both diagnostic and therapeutic purposes in sepsis. The nanoparticle (NP)‐enabled capture of sepsis causative agents and/or sepsis biomarkers in biofluids can revolutionize sepsis diagnosis. From the therapeutic point of view, currently existing nanoscale drug delivery systems have proven to be excellent allies in targeted therapy, while many other nanotherapeutic applications are envisioned. Herein, the most relevant applications of nanomedicine for the diagnosis, prognosis, and treatment of sepsis is reviewed, providing a critical assessment of their potentiality for clinical translation.

show abstract

Testing Antifungal Vaccines in an Animal Model of Invasive Candidiasis and in Human Mucosal Candidiasis

Cited by 7 publications

References 26 publications

Experimental In Vivo Models of Candidiasis

Experimental In Vivo Models of Candidiasis

Old Wine in a New Bottle-Focus on Candidial Vaccine

Nanotools for Sepsis Diagnosis and Treatment

Contact Info

Product

Resources

About